BioLife Solutions combines a high-moat, 98%-consumables CGT franchise with a Repligen cash-and-stock merger, offering a $48.35 five-year expected value despite deal-execution risk.
Overview
BioLife Solutions is a specialized life-science tools company supplying clinical-grade biopreservation media, cell-processing tools, hPL supplements, and thawing products to the cell and gene therapy ecosystem. Its strategic divestitures of Stirling Ultracold in 2024 and SAVSU in 2025 removed low-margin equipment and logistics operations, leaving a **pure-play consumables model with approximately 98% recurring pro forma revenue**. Biopreservation media contributes roughly 87% of revenue, and BioLife holds more than 70% share of U.S. commercially sponsored cell-based clinical trials, with products embedded in 18 commercially approved therapies as of June 30, 2026. Q2 2026 revenue grew 21.4% year over year to $28.47 million, adjusted EBITDA rose 32.1% to $7.40 million, and adjusted EBITDA margin reached 26.0%. Full-year 2026 standalone revenue guidance remains $112.5 million–$115.0 million, or 17%–20% organic growth, with mid-60% gross margins and positive GAAP net income. The pending $1.5 billion Repligen merger provides $11.25 cash plus 0.1442 RGEN shares per BLFS share; at RGEN’s $176.36 price, implied consideration is $36.68 versus BLFS at $36.95. **Near-term catalysts are the Q4 2026 vote, HSR clearance, and eight potential therapy approvals or rollouts.**